The Durability of Basal Insulin Affects Day-to-Day Glycemic Variability Assessed by Continuous Glucose Monitoring in Type 2 Diabetes Patients: A Randomized Crossover Trial

被引:11
作者
Iuchi, Hiroyuki [1 ]
Sakamoto, Masaya [1 ]
Matsutani, Daisuke [1 ]
Suzuki, Hirofumi [1 ]
Horiuchi, Ryuzo [2 ]
Utsunomiya, Kazunori [1 ]
机构
[1] Jikei Univ, Sch Med, Dept Internal Med, Div Diabet Metab & Endocrinol, Tokyo 1058461, Japan
[2] Tsuruoka Kyoritu Hosp, Yamagata, Japan
关键词
Type; 2; diabetes; Basal insulin; Glycemic variability; Continuous glucose monitoring; Glargine; ACTING INSULIN; HYPOGLYCEMIA; GLARGINE; MELLITUS; ADOLESCENTS; PROFILES;
D O I
10.1089/dia.2017.0028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Not only within-day glycemic variability but also day-to-day glycemic variability is a risk factor for diabetic patients. However, the ways of controlling day-to-day glycemic variability are unclear. We hypothesized that the durability of basal insulin plays an important role in controlling day-to-day glycemic variability in type 2 diabetes patients, and we therefore aimed to evaluate whether glargine U300, which exhibits prolonged absorption compared with glargine U100 but the same composition as glargine U100, would lead to improved day-to-day glycemic variability. Materials and Methods: This was a single-center, randomized, open-label, crossover study in type 2 diabetes patients using basal insulin therapy. After switching from 4 weeks of treatment with glargine U100 or U300, the patients performed continuous glucose monitoring (CGM) for 72 h in an environment with routine activities and mealtimes. The mean of daily difference (MODD) was assessed as day-to-day glycemic variability. Results: We enrolled 22 patients, and 17 patients completed the study. The MODD assessed as day-to-day glycemic variability was significantly lower with glargine U300 than with glargine U100 (1.8 +/- 0.6 mmol/L vs. 2.4 +/- 0.9 mmol/L, P = 0.006). No significant difference was observed in short-term glycemic variability between the two glargine formulations as measured by the standard deviation, coefficient of variation, mean amplitude of glucose excursion. Conclusions: Compared with glargine U100 treatment, glargine U300 treatment improved the MODD as assessed by CGM in type 2 diabetes patients. These findings suggest that the durability of basal insulin may be associated with day-to-day glycemic variability in type 2 diabetes patients.
引用
收藏
页码:457 / 462
页数:6
相关论文
共 50 条
[41]   A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes [J].
Daher Vianna, Andre Gustavo ;
Lacerda, Claudio Silva ;
Pechmann, Luciana Muniz ;
Polesel, Michelle Garcia ;
Marino, Emerson Cestari ;
Faria-Neto, Jose Rocha .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 139 :357-365
[42]   Basal Insulin Degludec and Glycemic Control Compared to Aspart Via Insulin Pump in Type 1 Diabetes (BIGLEAP): A Single-Center, Open-Label, Randomized, Crossover Trial [J].
Lane, Wendy S. ;
Weinrib, Stephen L. ;
Lawrence, Michael J. ;
Lane, Benjamin C. ;
Jarrett, Ryan T. .
ENDOCRINE PRACTICE, 2022, 28 (02) :165-172
[43]   A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naive patients with type 2 diabetes: the IMAGINE 6 trial [J].
Grunberger, G. ;
Chen, L. ;
Rodriguez, A. ;
Tinahones, F. J. ;
Jacober, S. J. ;
Bue-Valleskey, J. .
DIABETES OBESITY & METABOLISM, 2016, 18 :34-42
[44]   Long-term glycemic control and glucose variability assessed with continuous glucose monitoring in a pediatric population with type 1 diabetes: Determination of optimal sampling duration [J].
Piona, Claudia ;
Marigliano, Marco ;
Mozzillo, Enza ;
Franzese, Adriana ;
Zanfardino, Angela ;
Iafusco, Dario ;
Maltoni, Giulio ;
Zucchini, Stefano ;
Delvecchio, Maurizio ;
Maffeis, Claudio .
PEDIATRIC DIABETES, 2020, 21 (08) :1485-1492
[45]   Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: The COBIN2 study [J].
Zdarska, Denisa Janickova ;
Kvapil, Milan ;
Rusavy, Zdenek ;
Krcma, Michal ;
Broz, Jan ;
Krivska, Bohumila ;
Kadlecova, Pavla .
WIENER KLINISCHE WOCHENSCHRIFT, 2014, 126 (7-8) :228-237
[46]   Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections A Randomized Trial [J].
Beck, Roy W. ;
Riddlesworth, Tonya D. ;
Ruedy, Katrina ;
Ahmann, Andrew ;
Haller, Stacie ;
Kruger, Davida ;
McGill, Janet B. ;
Polonsky, William ;
Price, David ;
Aronoff, Stephen ;
Aronson, Ronnie ;
Toschi, Elena ;
Kollman, Craig ;
Bergenstal, Richard .
ANNALS OF INTERNAL MEDICINE, 2017, 167 (06) :365-+
[47]   Improved glycemic control with once-weekly dulaglutide in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring [J].
Yajima, Takahiro ;
Yajima, Kumiko ;
Hayashi, Makoto ;
Takahashi, Hiroshi ;
Yasuda, Keigo .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2018, 32 (03) :310-315
[48]   An exploratory trial of insulin initiation and titration among patients with type 2 diabetes in the primary care setting with retrospective continuous glucose monitoring as an adjunct: INITIATION study protocol [J].
Blackberry, Irene D. ;
Furler, John S. ;
Ginnivan, Louise E. ;
Derraz, Hanan ;
Jenkins, Alicia ;
Cohen, Neale ;
Best, James D. ;
Young, Doris ;
Liew, Danny ;
Ward, Glenn ;
Manski-Nankervis, Jo-Anne ;
O'Neal, David N. .
BMC FAMILY PRACTICE, 2014, 15
[49]   Continuous Glucose Monitor Use Prevents Glycemic Deterioration in Insulin-Treated Patients with Type 2 Diabetes [J].
Karter, Andrew J. ;
Parker, Melissa M. ;
Moffet, Howard H. ;
Gilliam, Lisa K. ;
Dlott, Richard .
DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 (05) :332-337
[50]   Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial [J].
Zhang, Tong ;
Lin, Mingrun ;
Li, Wangen ;
Fan, Xiuyun ;
Du, Tao ;
Zhao, Yunjuan ;
Zhang, Xiaodan .
ADVANCES IN THERAPY, 2016, 33 (02) :178-185